3 Jul

An Update on Johnson & Johnson’s Immunology Business

WRITTEN BY Daniel Collins FEATURED IN Company News, Insights, & Analysis

Immunology business’s revenue trends

In the first quarter, Johnson & Johnson’s (JNJ) Immunology business generated revenues of $3.0 billion compared to $2.9 billion in the first quarter of 2017, which reflected ~3.8% YoY (year-over-year) growth.

In the first quarter, Johnson & Johnson’s Immunology business generated revenues of $2.0 billion and $1.0 billion from the US and international markets, respectively, reflecting an ~5.8% YoY decline and ~29.0% YoY growth.

An Update on Johnson & Johnson’s Immunology Business

Remicade and Simponi: Revenue trends

Johnson & Johnson’s Remicade generated revenues of $1.4 billion in the first quarter compared to $1.7 billion in the first quarter of 2017, which reflected an ~17.0% YoY decline.

Remicade generated first-quarter revenues of $916.0 million and $331.0 million from sales in the US and international markets, respectively, compared to $1.1 billion and $325.0 million in the first quarter of 2017. This represents an ~22.5% decline and 1.8% growth on a YoY basis.

Johnson & Johnson’s Simponi reported revenues of $518.0 million in the first quarter compared to $428.0 million in the first quarter of 2017, which is ~21.0% YoY growth.

In the US and international markets, Simponi generated first-quarter revenues of $224.0 million and $294.0 million, respectively, compared to $229.0 million and $199.0 million in the first quarter of 2017. This represents an ~2.2% decline and 47.7% growth on a YoY basis.

Stelara’s revenue trends

Stelara reported net revenues of $1.1 billion in the first quarter compared to $823.0 million in the first quarter of 2017, reflecting ~28.9% YoY growth. Stelara generated first-quarter revenues of $652.0 million and $409.0 million from its sales in the US and international markets, respectively, which is ~19.2% and ~48.2% growth on a YoY basis.

Stelara is used to treat moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn’s disease. Stelara’s peers Novartis’s (NVS) Cosentyx and Eli Lilly’s (LLY) Taltz reported first-quarter revenues of $580.0 million and $147.0 million, respectively.

Latest articles

Yesterday, Apple (AAPL) launched a newly upgraded range of its iPad Air and iPad mini devices ahead of its March 25 special event.

19 Mar

Nike Gears Up to Deliver Its Q3 2019 Results

WRITTEN BY Sharon Bailey

Nike (NKE) is scheduled to report its earnings results for the third quarter of fiscal 2019 after the market closes on March 21.

On March 18, Chesapeake Energy’s (CHK) implied volatility was 51.9%, which is ~14.7% less than its 15-day average.

19 Mar

Sprint’s Revenue and Earnings Growth

WRITTEN BY Andrew Smith

Sprint (S) reported an adjusted EPS of $0.06 in the first nine months of fiscal 2018—compared to $0.08 during the same period in fiscal 2017.

19 Mar

Oil Bulls: US Oil Exports Tend to Fall More

WRITTEN BY Robert Scott

On March 18, Brent crude oil May futures settled ~$8.2 higher than the WTI crude oil May futures. On March 11, the spread was ~$9.5.

Out of the 34 analysts covering Broadcom (AVGO), 25 analysts rated the stock a “buy,” while nine analysts rated the stock a “hold."